These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34633259)

  • 1. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways.
    Mekonnen D; Mengist HM; Jin T
    Expert Rev Vaccines; 2022 Jan; 21(1):69-81. PubMed ID: 34633259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
    Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
    Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
    Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19).
    Córdova-Martínez A; Caballero-García A; Roche E; Noriega DC
    Int J Environ Res Public Health; 2021 Nov; 18(23):. PubMed ID: 34886361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant.
    Zhang N; Ji Q; Liu Z; Tang K; Xie Y; Li K; Zhou J; Li S; Shang H; Shi Z; Zheng T; Yao J; Lu L; Yuan S; Jiang S
    Viruses; 2022 Feb; 14(3):. PubMed ID: 35336907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
    Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
    Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines.
    Peletta A; Lemoine C; Courant T; Collin N; Borchard G
    Pharmacol Res; 2023 Mar; 189():106699. PubMed ID: 36796463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positively Charged-Amylose-Entangled Au-Nanoparticles Acting as Protein Carriers and Potential Adjuvants to SARS-CoV-2 Subunit Vaccines.
    Fan B; Gu J; Deng B; Guo W; Zhang S; Li L; Li B
    ACS Appl Mater Interfaces; 2023 Jun; 15(25):29982-29997. PubMed ID: 37330942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvants for Coronavirus Vaccines.
    Liang Z; Zhu H; Wang X; Jing B; Li Z; Xia X; Sun H; Yang Y; Zhang W; Shi L; Zeng H; Sun B
    Front Immunol; 2020; 11():589833. PubMed ID: 33240278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
    Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
    Front Immunol; 2022; 13():992062. PubMed ID: 36569949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review.
    Sandoval C; Guerrero D; Muñoz J; Godoy K; Souza-Mello V; Farías J
    Expert Rev Vaccines; 2023; 22(1):35-53. PubMed ID: 36484136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy.
    Ameratunga R
    Expert Rev Vaccines; 2022 Sep; 21(9):1177-1184. PubMed ID: 35695410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crafting Immunological Response Using Particulate Vaccines.
    Bansal A; D'Souza B; Kapoor DN; Singh P; Starr G; Muppireddy KK
    Crit Rev Ther Drug Carrier Syst; 2022; 39(4):49-82. PubMed ID: 35695658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
    Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
    Buntinx E; Brochado L; Borja-Tabora C; Yu CY; Alberto ER; Montellano MEB; Carlos JC; Toloza LB; Hites M; Siber G; Clemens R; Ambrosino D; Qin H; Chen HL; Han HH; Hu B; Li P; Baccarini C; Smolenov I
    Vaccine; 2023 Mar; 41(11):1875-1884. PubMed ID: 36781334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.